Fianlimab

The LAG-3 next-generation immunotherapies market is projected to grow from $463.6 million in 2024 to $5.5 billion by 2035, driven by increasing solid tumor cases and expanding treatment options.

Pfizer is prioritizing its oral obesity drug, danuglipron, with late-stage studies planned for the second half of 2025, aiming for a novel mechanism of action.

Phase 3 C-POST trial reveals adjuvant Libtayo (cemiplimab) significantly improves disease-free survival (DFS) in high-risk cutaneous squamous cell carcinoma (CSCC) patients after surgery.

Fianlimab plus cemiplimab demonstrates durable efficacy and a better-tolerated safety profile compared to ipilimumab and nivolumab in advanced melanoma, showing promise in ongoing adjuvant and frontline metastatic studies.

The combination of fianlimab and cemiplimab demonstrates a 57% overall response rate (ORR) in advanced melanoma patients, regardless of PD-L1 or LAG-3 status.